Supplementary Figure 1:
Validation of the mutants by sequencing and phenotypic assays. Panels A and B showed the bi-allelic mutations were validated by PCR and sequencing. Specifically, the insertion of the cassette into the correct locus was confirmed by visualising on 1% E-gel (Life Tech) PCR products of indicated sizes were generated by gene specific (GF1 and GR1) and cassette specific (ER and PF) primers for both 5' and 3' ends (Supplementary Data 1 and Panel A). To check the CRISPR site on the non-targeted allele, PCR products were generated either from across the locus, using the 5' and the 3' gene specific genotyping primers (GF1-GR1), or from around the site using primers 5F-3R (Supplementary Data 1) that would amplify a short, around 500 bp, amplicon. In both cases the PCR products were treated with exonuclease and alkaline phosphatase (NEB) and Sanger sequenced using primers SF and SR (Supplementary Data 1 and Panel B). Both mutant human iPS lines were able to differentiate into macrophages and expressed macrophage markers (CD11b, CD14, CD16, CD68 as measured by flow cytometry; red histograms represent cells stained with control isotype and blue histograms represent cells stained with relevant antibody; Panel C). Both mutant iPSdMs showed an ability to phagocytose using pHrodo Green dye-labeled E.coli (ThermoFisher) 
